🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#CRISPR isn’t living up to its potential. Thousands of rare diseases that could be treated with gene editing remain untouched by drug companies. Two scientists, Fyodor Urnov + Kiran Musunuru, have a plan to fix that. Read more in my deep dive for Endpoints News: endpts.com/crispr-isnt-li…

Patrick Hsu's Patrick Hsu startup Stylus Medicine has launched with $85M to develop a recombinase-based gene insertion tech that is simpler than similar CRISPR-based approaches, with an initial focus on in vivo CAR-T. My exclusive for Endpoints News has the details: endpts.com/exclusive-patr…

🎙️Let's talk "most favored nation"! Today on Post-Hoc Live, I'll be joined by biotech lobbyist Nick Shipley to unpack the last 24 hours of Trump's drug pricing exec order, how it would work (or not), unintended consequences + what happens next. Join us! endpts.com/endpoints-live…

In an anticipated update for the gene insetion field, David R. Liu and Sam Sternberg have figured out how to get #CRISPR-associated transposases to insert full genes efficiently in human cells. Lei Lei Wu and I have the details in our story for Endpoints News: endpts.com/david-liu-sam-…

So CRISPR Therapeutics surprised me yesterday when it partnered with an #siRNA company. After all, isn't #CRISPR gene editing supposed to do anything that siRNA can do, only permanently? I talked to CEO Samarth Kulkarni to learn more in my latest for Endpoints News: endpts.com/crispr-therape…

Here's a wild idea: attach a cocaine-like molecule to the surface of a torn-up adenovirus and inject it in chronic drug users to help them develop antibodies that prevent cocaine from reaching the brain. I have the details of the first results in Endpoints News: endpts.com/researchers-re…

Casma Tx has raised more than $150 million since it launched in 2018 to develop drugs that target autophagy. It's presenting its first preclinical data in Gaucher's disease this week, but recently trimmed its staff to 5 employees. Read more in Endpoints News: endpoints.news/after-layoffs-…

I'm looking forward to breaking down this story with Dr. Cohen at 3:00pm ET. If you're looking for a primer on ACIP, and how its dismantling could affect the price and uptake of vaccines moving forward, tune in. We'll also address the broader message this sends to public health.

In another interesting alternative to animal models, the organoid startup Parallel Bio has raised $21 million to test drugs and vaccines in its lymph node-in-a-dish technology, sourced from 100 human tissue donors. Read more in my exclusive for Endpoints News - endpoints.news/organoid-start…